ArticleProbiotics and antimicrobial proteins2025
A Novel Type I Crustin Isoform from Scylla olivacea and its Antibacterial Potential: Membrane Depolarization, Disruption, and Induction of Reactive Oxygen Species as Modes of Action.
Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RpaA Overexpression Enhances Bioluminescence Intensity and Elevates Rhythmic Extracellular Vesicle Yield inLife (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Availability of novel antimicrobial agents is an urgent necessity to combat the growing threat posed by multidrug-resistant bacteria, prompting exploration of marine antimicrobial peptides (AMPs) as potential solutions. Crustacean AMPs are equitably diverse in terms of structure and function, making them consistent templates for novel antimicrobials. From Scylla olivacea gill transcriptome cDNA, a putative Crustin AMP sequence of 333 nucleotides, encoding a 111 amino acid Crustin Type-I isoform was identified. The mature peptide encoding region was cloned and recombinantly expressed in E. coli using Luria Bertani (LB) broth, yielding approximately 0.9 mg/L peptide. This cationic (+6.25) peptide with amphipathic properties (34% hydrophobicity) exhibited antibacterial effects against Gram-positive and Gram-negative strains, with MIC 16 μM against Vibrio spp. The identified modes of actions included disruption of bacterial membranes, membrane potential dissipation, and induction of ROS. Scanning electron microscopy (SEM) analysis revealed bacterial lysis and structural damage. Being non-toxic to mammalian cells (CHO-K1) and non-haemolytic, So-Crustin qualifies to be safe for therapeutic applications. It was quite stable under different physio-chemical/biological conditions, including temperature, pH, NaCl concentrations and proteases like trypsin and proteinase K. This study emphasizes So-Crustin's potential as a safe and effective antibacterial agent.
Indexed as
Identifiers
39946008What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.